首页 > 资讯 > Regeneron首席执行官表示，Ozempic等流行减肥药物存在健康风险，该公司表示，其肥胖药物的目标是保护肌肉

Regeneron首席执行官表示，Ozempic等流行减肥药物存在健康风险，该公司表示，其肥胖药物的目标是保护肌肉

泰然健康网
2024-12-17 09:21

George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc REGN, has voiced concerns that the popular GLP-1s class of weight-loss drugs may lead to unintended health risks, particularly rapid muscle loss.

Regeneron Pharmaceuticals Inc REGN的联合创始人兼首席科学官乔治·扬科波洛斯（GeorgeYancopoulos）表示担心，广受欢迎的GLP-1s类减肥药可能会导致意外的健康风险，尤其是快速的肌肉损失。

Yancopoulos warned that unless this side effect is mitigated, these treatments could ultimately cause “more harm than good.” Clinical studies indicate that patients using GLP-1s, such as Novo Nordisk A/S’ NVO Ozempic and Wegovy, experience muscle loss much faster than those who lose weight through diet and exercise..

Yancopoulos警告说，除非减轻这种副作用，否则这些治疗最终可能导致“弊大于利”。临床研究表明，使用GLP-1s的患者，如诺和诺德A/S的NVO Ozempic和Wegovy，比那些通过饮食和运动减肥的患者经历肌肉损失的速度要快得多。。

U.S. pharmacy claims data analysis reveals that only one in four patients prescribed Wegovy and Ozempic continue their treatment after two years.

U、美国药房索赔数据分析显示，处方Wegovy和Ozempic的患者中只有四分之一在两年后继续治疗。

In the Financial Times report, Yancopoulos emphasized that patients often regain weight but with a higher fat-to-muscle ratio, which Yancopoulos described as “adding insult to injury.”

在《金融时报》的报告中，Yancopoulos强调，患者通常会恢复体重，但脂肪与肌肉的比例更高，Yancopoulos将其描述为“对伤害的侮辱”

He expressed concerns that GLP-1s may trigger body composition changes that could lead to more harm than benefit in the long run when used in the real world.

他表示担心GLP-1可能会引发身体成分的变化，从长远来看，在现实世界中使用GLP-1可能会导致弊大于利。

A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.

发表在《美国医学会杂志》（JAMA）上的一项研究显示，服用药物一年后，患者平均体重减轻了3.7%，低于对照试验报告的结果。

Regeneron is researching muscle-preserving treatments to pair with these weight-loss medications.

Regeneron正在研究肌肉保护疗法，以与这些减肥药物搭配使用。

Regeneron is conducting a Phase 2 trial for trevogrumab, which blocks the hormone myostatin to promote muscle growth, in combination with Wegovy (semaglutide).

Regeneron正在进行trevogrumab的2期试验，该试验与Wegovy（semaglutide）联合使用，可阻断激素肌肉生长抑制素促进肌肉生长。

Topline results are expected in the second half of 2025.

。

In June, Regeneron released multiple ascending dose data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab on body composition in healthy volunteers (n=34).

6月，Regeneron发布了一项1期研究的多个递增剂量数据，该研究评估了garetosmab（抗激活素a）和trevogrumab对健康志愿者（n=34）身体成分的影响。

The data demonstrated that combination therapy led to greater-than-additive increases in lean mass while decreasing fat mass in healthy participants.

数据表明，联合治疗导致健康参与者的瘦体重增加超过加和，同时减少脂肪量。

In 2023, Eli Lilly And Co LLY acquired Versanis Bio for up to $1.925 billion in cash, bolstering its product profile of obesity-curbing drugs.

2023年，礼来公司（Eli Lilly）和LLY公司（Co-LLY）以高达19.25亿美元的现金收购了Versanis Bio，从而巩固了其减肥药物的产品形象。

Eli Lilly said bimagrumab can reduce fat mass while preserving muscle mass for people with obesity and obesity-related complications.

礼来说，比马单抗可以减少肥胖和肥胖相关并发症患者的脂肪量，同时保持肌肉质量。

According to FT, Yancopoulos hinted that Regeneron is considering entering the GLP-1 space by developing its drug version despite the concern. However, he remains cautious, stating that GLP-1s may not be the ultimate solution to metabolic disease.

据英国《金融时报》报道，Yancopoulos暗示，尽管存在担忧，Regeneron仍在考虑通过开发其药物版本进入GLP-1领域。然而，他仍然保持谨慎，指出GLP-1s可能不是代谢疾病的最终解决方案。

Price Action: REGN stock is down 0.23% tot $1,010.51 at the last check on Monday.

价格走势：瑞金股价下跌0.23%，至周一最后一次检查时的1010.51美元。

Taiwan Semiconductor Strengthens Europe’s Semiconductor Base.

台湾半导体巩固了欧洲的半导体基础。

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.